Transformative therapies for vascular disease

Vasa Therapeutics, a San Diego-based, private biotechnology company committed to the discovery and development of best-in-class therapeutics for the treatment of heart failure, peripheral artery disease, sarcopenia and other vascular diseases.

The Problem

There’s a significant unmet medical need for the development and commercialization of innovative drugs and therapeutics for cardiovascular and other vascular related disorders and diseases, such as PAD and Sarcopenia.

CVD

Cardiovascular disease is the leading cause of mortality and morbidity globally accounting for more than 17 million deaths worldwide each year a figure expected to reach over 23 million per year by 2030. The long-term prognosis associated with heart failure is worse than all but a few cancers, with 50% mortality after 4 years. By 2030 nearly half of the US population will suffer from CVD. This disease burden imposes substantial economic costs on societies, with 1–2% of all US healthcare expenditures, about $40B/year, going towards heart failure.

PAD

Peripheral artery disease is an atherosclerotic disease of the lower extremities associated with high cardiovascular mortality. PAD affects >230 million adults worldwide and is associated with increased risk of various adverse clinical outcomes and other cardiovascular diseases such as coronary heart disease and stroke and leg outcomes such as amputation. The prevalence of PAD rises with age and affects a substantial proportion of the elderly population (>20% in >80-year-old individuals). (ref: NCBI)

Over

230 million

Adults worldwide affected by PAD

Sarcopenia

Population of adults aged over 60 years old worldwide is predicted to expand to 2 billion by 2050. Sarcopenia is the most significant cause of disability and frailty in the elderly. The prevalence of sarcopenia among individuals 60-70 years of age is 5%-13% and increases to 50% in those over 80 years of age (EWGSOP). Global market size was $2.6B in 2020 and projected to grow to $4.7B by 2030.

Our Solution

Vasa has two active preclinical programs: one small molecule program focused on the treatment of cardiovascular disease (CVD) and one peptide therapeutic program aimed at identifying a novel treatment for Peripheral Artery Disease (PAD) and Sarcopenia.

Platform

At Vasa Therapeutics, the overall drug discovery process begins and ends with our cutting-edge computational chemistry and design platform. Our process integrates everything from the strategic identification of viable biological targets to the design and identification of small molecule or peptide therapeutics that are triaged through our drug discovery testing funnel in house and our network of strategic partnerships with international contract research organizations (CRO).

About Us

Investors

Vasa Therapeutics received a non-dilutive grant from European Union (details below) and a seed investment from Orphinic Scientific, an investment and development platform creating innovative solutions for orphan diseases and other indications with significant unmet medical needs (www.orphinic.com).

Company

Vasa Therapeutics, Inc. is a private, preclinical-stage biopharmaceutical company committed to the discovery and development of best-in-class therapies for the treatment of vascular disease. Vasa has locations in California and Poland, strategically placed in vibrant academic and biotechnology innovation centers.

Leadership

We are a world-class, founder-led team with an outstanding track record of successful development of numerous clinical candidates and commercial drugs spanning multiple therapeutic areas and modalities resulting in several exits valued at greater than $1B (USD).

Grant Projects

Preclinical development and phase I clinical trial of innovative drug candidate for heart failure with preserved ejection fraction (HFpEF) (POIR.01.01.01-00-1210/19-01).
‍
Project carried out within the Measure 4.1 "Research and development", Sub-measure 4.1.4 "Regional research agendas" as a part of the Operational Program Smart Growth 2014-2020 co-funded by the European Regional Development Fund.

Value of the project: 13 220 234,42 PLN
European Union financing: 10 186 082,76 PLN
‍
Objective of the project is preclinical research and phase I clinical trial of innovative small-molecule inhibitor of metalloproteinase MMP2, MMP9 and MMP13, addressing key pathophysiological components of heart failure with preserved ejection fraction (HFpEF) and utilizing role of
MMP2, MMP9 and MMP13 as molecular targets of this condition.

Contact

US Headquarters

Vasa Therapeutics, Inc.
533 2nd Street, Suite 350
Encinitas, CA 92024

Poland Lab and Office

Vasa Therapeutics, SP. Z.o.o.
St Leszczynskiego, 4/25,
50-078 Wroclaw, Poland

Interested in learning more? Contact us at:

info@vasatherapeutics.com